A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL).
Richard R. Furman
No relevant relationships to disclose
Jacqueline Claudia Barrientos
No relevant relationships to disclose
Jeff Porter Sharman
Honoraria - Calistoga Pharmaceuticals; Gilead Sciences
Sven De Vos
Consultant or Advisory Role - Gilead Sciences
John Leonard
Consultant or Advisory Role - Gilead Sciences; GlaxoSmithKline
Steven E. Coutre
No relevant relationships to disclose
Marshall T. Schreeder
No relevant relationships to disclose
Nina D. Wagner-Johnston
No relevant relationships to disclose
Thomas E. Boyd
No relevant relationships to disclose
Nathan Hale Fowler
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Ian W. Flinn
No relevant relationships to disclose
Ralph V. Boccia
No relevant relationships to disclose
Leanne Holes
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Brian Joseph Lannutti
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Dave Johnson
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Thomas Michael Jahn
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Langdon L. Miller
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences